Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Nina S. Kjellson sold 1,076 shares of the stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $17.01, for a total transaction of $18,302.76. Following the transaction, the director now owns 458,390 shares of the company's stock, valued at approximately $7,797,213.90. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Tyra Biosciences Trading Up 2.1 %
TYRA opened at $17.12 on Thursday. The stock's fifty day simple moving average is $22.09 and its 200 day simple moving average is $19.96. Tyra Biosciences, Inc. has a 1-year low of $10.60 and a 1-year high of $29.60. The stock has a market cap of $904.11 million, a PE ratio of -10.13 and a beta of 1.08.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.09. Equities analysts forecast that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.
Institutional Inflows and Outflows
Election warning coming true…
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
Click here to watch it now.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Oppenheimer & Co. Inc. acquired a new stake in Tyra Biosciences during the 1st quarter worth approximately $977,000. Vanguard Group Inc. boosted its position in shares of Tyra Biosciences by 18.6% in the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company's stock valued at $14,757,000 after acquiring an additional 140,833 shares during the period. BVF Inc. IL boosted its position in shares of Tyra Biosciences by 70.1% in the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company's stock valued at $76,444,000 after acquiring an additional 1,921,599 shares during the period. Kynam Capital Management LP grew its stake in shares of Tyra Biosciences by 51.4% in the first quarter. Kynam Capital Management LP now owns 515,190 shares of the company's stock valued at $8,449,000 after acquiring an additional 175,000 shares in the last quarter. Finally, RA Capital Management L.P. increased its position in Tyra Biosciences by 43.9% during the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company's stock worth $170,832,000 after acquiring an additional 3,180,155 shares during the period. Institutional investors and hedge funds own 84.14% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts recently commented on TYRA shares. Piper Sandler began coverage on Tyra Biosciences in a research report on Thursday, August 15th. They set an "overweight" rating and a $33.00 price target for the company. Bank of America upgraded Tyra Biosciences from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Oppenheimer raised their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an "outperform" rating in a research note on Thursday, September 19th. Wedbush reaffirmed an "outperform" rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. Finally, HC Wainwright lifted their price objective on shares of Tyra Biosciences from $30.00 to $32.00 and gave the company a "buy" rating in a research report on Monday, October 28th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $31.40.
View Our Latest Analysis on Tyra Biosciences
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
